SciClone to Present at Four Investor Conferences in September 2013
FOSTER CITY, CA -- (Marketwired) -- 09/04/13 -- SciClone
Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that the Company
will present a corporate overview and business update at four
upcoming investor conferences in September 2013.
Friedhelm Blobel, PhD, Chief Executive Officer, will present at the
Morgan Stanley Global Healthcare Conference on Wednesday, September
11th at 10:35 am ET at the Grand Hyatt Hotel in New York City, NY.
Dr. Blobel will participate in a panel discussion, titled "BD in
China: Why Now is the Time to Partner with Domestics," at the
Elsevier Pharmaceutical Strategic Alliances (PSA) conference on
Wednesday, September 25th at 9:20 am ET at the Millennium Broadway
Hotel in New York City, NY.
Wilson W. Cheung, Chief Financial Officer, will present at the Aegis
Capital Corporation 2013 Healthcare Conference on Thursday, September
26th at 11:30 am PT at the Encore at Wynn Hotel in Las Vegas, NV.
Dr. Blobel will present at the BioCentury NewsMakers in the Biotech
Industry conference on Friday, September 27th at 11:00 am ET at the
Millennium Broadway Hotel in New York City, NY.
To access the live audio webcasts of the Morgan Stanley and
BioCentury NewsMakers presentations, please log on through a link
located in the Investor Relations section of SciClone's website at
www.sciclone.com, under the Calendar of Events tab. A replay of the
webcasts will be available one hour after the conclusion of the live
SciClone Pharmaceuticals is a revenue-generating, specialty
pharmaceutical company with a substantial commercial business in
China and a product portfolio of therapies for oncology, infectious
diseases and cardiovascular, urological, respiratory, and central
nervous system disorders. SciClone's proprietary lead product,
ZADAXIN(R) (thymalfasin), is approved in over 30 countries and may be
used for the treatment of hepatitis B (HBV), hepatitis C (HCV), and
certain cancers, and as a vaccine adjuvant, according to the local
regulatory approvals. Through its promotion business with
pharmaceutical partners, SciClone markets multiple branded products
in China which are therapeutically differentiated. The Company has
successfully in-licensed products with the potential to become future
market leaders and to drive the Company's long-term growth. SciClone
is a publicly-held corporation based in Foster City, California, and
trades on the NASDAQ Global Select Market under the symbol SCLN. For
additional information, please visit www.sciclone.com.
This press release contains forward-looking statements regarding
expected financial results and expectations. Readers are urged to
consider statements that include the words "may," "will," "would,"
"could," "should," "might," "believes," "estimates," "projects,"
"potential," "expects," "plans," "anticipates," "intends,"
"continues," "forecast," "designed," "goal," "unaudited,"
"approximately" or the negative of those words or other comparable
words to be uncertain and forward-looking. These statements are
subject to risks and uncertainties that are difficult to predict and
actual outcomes may differ materially. Please also refer to other
risks and uncertainties described in SciClone's filings with the SEC.
All forward-looking statements are based on information currently
available to SciClone and SciClone assumes no obligation to update
any such forward-looking statements.
SciClone, SciClone Pharmaceuticals, the SciClone Pharmaceuticals
design, the SciClone logo and ZADAXIN are registered trademarks of
SciClone Pharmaceuticals, Inc. in the United States and numerous
Wilson W. Cheung
Chief Financial Officer
Press spacebar to pause and continue. Press esc to stop.